View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, March 7 (HealthDay News) -- A combined approach using methylated DNA immunoprecipitation (MeDiP) and real-time quantitative PCR (qPCR) of maternal peripheral blood allows noninvasive prenatal diagnosis (NIPD) of trisomy 21 (Down's syndrome), according to research published online March 6 in Nature Medicine.
Elisavet A. Papageorgiou, Ph.D., from the Cyprus Institute of Neurology and Genetics in Nicosia, and colleagues evaluated the use of a noninvasive analysis of fetal-specific differentially methylated regions (DMRs) using combined MeDiP methodology and real-time qPCR to assess fetal chromosome dosage. Twelve fetal-specific DMRs (EP1 to EP12) in maternal peripheral blood samples from 20 normal and 20 trisomy 21 cases, and 40 blinded cases were analyzed.
The investigators found that, of the DMRs tested, EP1, EP4, EP7, and EP10 could discriminate between normal cases and trisomy 21 cases, but EP8 and EP11 could not. Using a combination of DMRs improved diagnostic sensitivity and specificity. Using this combined DMR approach all the known samples (20 normal and 20 trisomy 21) were correctly identified, and 26 normal and 14 trisomy 21 cases were correctly diagnosed in the blinded group.
"The approach described here has opened the way for NIPD of trisomy 21 to be potentially employed in the routine practice of all diagnostic laboratories and be applicable to all pregnancies," the authors write.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top